Moneycontrol
Get App
SENSEX NIFTY
you are here:

Nutraplus India Ltd.

BSE Live

Apr 07, 16:00
5.29 0.08 (1.54%)
Volume
AVERAGE VOLUME
5-Day
3,047
10-Day
2,258
30-Day
5,057
18,089
  • Prev. Close

    5.21

  • Open Price

    5.31

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

(%)
Volume
No Data Available
  • Prev. Close

  • Open Price

  • Bid Price (Qty.)

    ()

  • Offer Price (Qty.)

    ()

Nutraplus India is not listed on NSE

Annual Report

For Year :
2016

Chairman's Speech

Chairman''s Message

Dear Shareholders,

Our success over the past several years has been a manifestation of our ability to develop quality bulk drugs at an economical price. As we move towards higher growth, our ability to retain these capabilities will help us achieve new heights of success and drive consistent growth in profitability.

I am pleased to announce that despite turbulent market conditions, our Company has witnessed strong performance during the year under review, with an annual revenue growth of 19.4%. Additionally, we have recommended a maiden dividend of Rs. 0.50 per fully paid up equity share for the year ended 31 March, 2016. This has highlighted our focus on value maximization of our stakeholders and our ability to sustain even in difficult macroeconomic conditions.

During the year, we have approved the amalgamation of Vetpharma Limited with the Company (subject to various regulatory approvals) which is expected to generate significant operational efficiencies for our organization. The merger is expected to create significant value for our stakeholders by widening the product portfolio and integrating technological prowess. During the year, we have also developed a new manufacturing facility at Tarapur, Boisar. Our blueprint for growth includes focus on expanding our production facilities to penetrate new areas of therapeutic treatments. We have made progress towards the same by acquiring land for a production facility in Dahej, Gujarat, which would further enhance our manufacturing footprint. The land has been allotted for the project, pending government approvals. We expect to begin commercial operations at this facility in about 18 months, post receiving the requisite approvals.

We also commenced full-fledged commercial production of an anti-malarial drug in January 2016. Previously, we were involved in the production of the intermediate of the same drug at our existing facility, but now we manufacture the end product. We have already received the necessary approvals for the same and expect this forward integration strategy to result into margin expansion. During the year, we divested our entire stake in the wholly-owned subsidiary, Nutraplus Generic Medicines & Health Care Products Limited. We also initiated a new project by incorporating 100% subsidiary, Purecare Pharma Limited. The subsidiary is being created to regain our footprint in the Anti-Biotic, Anti-Bacterial and Cephalosporin segments.

I would like to thank our shareholders for their trust and confidence in the Company''s future prospects. We believe that a focused production approach, robust product portfolio, aggressive growth strategy, in-house installation expertise, strategic partnerships and alliances, quality talent pool and stringent systems and processes would help us to deliver continuous growth. The shareholders continued support and commitment towards our Company has motivated us to enrich our processes and take a higher leap of growth. In the long term, expansion of production capacity and increased operational efficiency would help us to deliver profitable growth.

I would once again like to thank our shareholders for their support and I remain confident that Nutraplus would deliver excellent long-term returns to shareholders.

Mukesh D. Naik